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Abstract The exposure to high glucocorticoids (GC) trig-
gers neuronal atrophy and cognitive deficits, but the exact
cellular mechanisms underlying the GC-associated den-
dritic remodeling and spine loss are still poorly under-
stood. Previous studies have implicated sustained GC ele-
vations in neurodegenerative mechanisms through GC-
evoked hyperphosphorylation of the cytoskeletal protein
Tau while Tau mislocation has recently been proposed as
relevant in Alzheimer’s disease (AD) pathology. In light of
the dual cytoplasmic and synaptic role of Tau, this study
monitored the impact of prolonged GC treatment on Tau
intracellular localization and its phosphorylation status in
different cellular compartments. We demonstrate, both by bio-
chemical and ultrastructural analysis, that GC administration
led to cytosolic and dendritic Tau accumulation in rat hippo-
campus, and triggered Tau hyperphosphorylation in epitopes
related to its malfunction (Ser396/404) and cytoskeletal pa-
thology (e.g., Thr231 and Ser262). In addition, we show, for
the first time, that chronic GC administration also increased
Tau levels in synaptic compartment; however, at the synapse,
there was an increase in phosphorylation of Ser396/404, but a
decrease of Thr231. These GC-triggered Tau changes were
paralleled by reduced levels of synaptic scaffolding proteins
such as PSD-95 and Shank proteins as well as reduced
dendritic branching and spine loss. These in vivo findings
add to our limited knowledge about the underlying mecha-
nisms of GC-evoked synaptic atrophy and neuronal discon-
nection implicating Tau missorting in mechanism(s) of synap-
tic damage, beyond AD pathology.
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Abbreviations
GC Glucocorticoids
MT Microtubules
AD Alzheimer’s disease
MWM Morris water maze
PSD-95 Postsynaptic density protein 95
DEX Dexamethasone
GluN2B NMDA receptor 2B
GluA2 AMPA receptor 2
ANOVA Analysis of variance
TEM Transmission electron microscopy
Introduction
Stress, largely through the elevation of circulating glucocorti-
coids (GCs), impacts on brain structure and function [1–4].
One of the most vulnerable brain areas is the hippocampus,
which exhibits remarkable dendritic atrophy and spine loss
after GC administration as well as in stress-related pathologies
characterized by high GC levels [1, 4]. However, the mecha-
nisms underlying these GC-induced deleterious effects that
damage hippocampus structural and functional integrity are
still poorly understood.
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Microtubule-associated protein Tau is implicated in cyto-
skeletal dynamics, as it stabilizes the microtubule (MT) net-
work [5]. While being mainly an axonal protein, Tau was
recently found in dendrites and synapses where it is suggested
to have novel signaling and scaffolding role(s), regulating
synaptic structure and function [5–8]. Recent human and an-
imals studies suggest that Tau hyperphosphorylation and its
mislocation in synapses may be related to synaptic pathology
in Alzheimer’s disease (AD) [9–12]. Our previous work
showed that stress and GC trigger Tau hyperphosphorylation
in neuronal somata [13, 14], but to date, there is no evidence
about the potential impact of dendritic/synaptic Tau on GC-
induced dendritic remodeling and spine loss. Thus, in the
present study, we used subcellular fractionation-based bio-
chemical analysis and electron microscopy to monitor Tau
dynamics and localization in hippocampal neurons of GC-
treated rats adding to our understanding of cellular phenomena
of GC-driven hippocampal malfunction and dendritic
remodeling.
Methods
Animals and Treatment
Three- to four-month-old maleWistar rats (Charles River Lab-
oratories, Spain) were paired housed under standard laborato-
ry conditions (8:00 A.M. to 8:00 P.M.; 22 °C; ad libitum
access to food and drink). Half of the animals were receiving
daily subcutaneous injections of the synthetic glucocorticoid,
dexamethasone (DEX) (300 μg/kg; Sigma D1756; dissolved
in sesame oil containing 0.01 % ethanol; sesame oil Sigma
S3547) for 14 sequential days, while control animals received
daily subcutaneous injections of sesame oil [1]. All experi-
mental procedures were approved by the local ethical commit-
tee of University of Minho and national authority for animal
experimentation; all experiments were in accordance with the
guidelines for the care and handling of laboratory animals, as
described in the Directive 2010/63/EU.
Behavioral Test
Spatial reference memorywas assessed using theMorris water
maze (MWM) test at the end of DEX treatment period. As
previously described [1, 13], testing was conducted in a cir-
cular black tank (170-cm diameter) filled with opaque water
(22 °C) and placed in a dimly lit room with extrinsic clues.
The tank was divided into virtual quadrants and had a black,
escaping platform (12-cm diameter) placed in one of them.
Animals (N=7–8 per group) were asked to find the escaping
platform over four consecutive days (four trials/day; 120-s
trial period). Note that there are no differences of swimming
speed between control and DEX-treated animals (data not
shown). On the 5 day (probe test), the animal had to search
(120 sec) for the escaping platform that was absent. Swim
paths of each animal were monitored and recorded by a
CCD camera, using a video tracking system (Viewpoint).
Neurostructural Analysis
As previously described [15], after animal perfusion with sa-
line, half of each brain (N=7–8 per group) were immersed in
Golgi-Cox solution for 14 days. After transfer to 30% sucrose
solution, vibratome-cut coronal brain sections (200 μm thick)
were used. After development, fixation and dehydration,
slides were used to perform three-dimensional morphometric
analysis. Dendritic arborization and spines were analyzed in
dorsal hippocampus (CA1 area). All branches of neuronal
dendritic tree (6–8 neurons/animal) were reconstructed at
×600 (oil) magnification using a motorized microscope
(Axioplan2, Zeiss) and Neurolucida software (MBF Biosci-
ence). For spine analysis, proximal and distal apical dendritic
segments (30 μm) were randomly selected and spines were
counted and further classified in immature (thin) and complex/
mature (mushroom, wide/thick, and ramified) categories as
previously described [15].
For electron microscope analysis, isolated hippocampi were
fixed (4 % PFA; 3 days; 4 °C), transferred to 4 %PFA/0.8 %
gluteraldehyde in 0.1 M of phosphate buffer (PB; pH 7.4) for
1 h and then, to 0.1 M PB (4 °C). Vibratome-cut axial sections
of the dorsal hippocampus (300 μm thick) were collected, and
the entire CA1 area was surgically removed. Tissue was then
carefully oriented and embedded in Epon resin and ultrathin
sections (500 Å), encompassing the superficial-to-deep axis,
were cut onto nickel grids. For Tau-immunogold staining, sec-
tions were treated with heated citrate buffer (1×; Thermo Sci-
entific, USA) for 30 min followed by 5 % BSA (Sigma, USA).
Grids were incubated overnight with the following primary
antibodies diluted in 1 % BSA (in PB): Tau-5 (1:30, Abcam),
pSer199/202-Tau (1:50 Abcam), pSer262-Tau (1:20, Santa
Cruz Biotechnology), pSer396 (1:50; Abcam), followed by
appropriate secondary gold antibody (1:15; Abcam). For man-
ual calculation of density of the above phospho-Tau, more than
50 nonoverlapping TEM (30,000×) of counterstained ultrathin
sections (60 nm) were used. Grids were observed on a JEOL
JEM-1400 transmission electron microscope equipped with a
Orious Sc1000 digital camera. Analysis was performed by an
experimenter blind to the samples provenience.
Subcellular Fractionation and Western Blot Analysis
For fractionation, we have used a well-established fraction-
ation protocol [8, 16]. As shown in Fig. 1g, dorsal hippocampi
(N=5 per group) were homogenized with 10 volumes of ho-
mogenization buffer [sucrose 9 %; 5 mMDTT; 2 mM EDTA;
25 mM Tris pH 7.4; complete protease inhibitor (Roche), and
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phosphatase inhibitor cocktails II and III (Sigma)] using a
Dounce glass homogenizer. Post-nuclear supernatant was sub-
jected to centrifugation (12,500g) and divided into the crude
synaptosomal fraction and synaptosome-depleted fraction.
The latest fraction was further subjected to ultracentrifugation
(176,000g), and separated into light membrane and Golgi
fraction (P3) and cytoplasmic fraction (S3) while crude syn-
aptosomal fraction was further lysed hypoosmotically and
centrifuged (25,000g) for 20 min in order to obtain the synap-
tosomal membrane fraction (LP1). S3 (1x) and LP1 (2x) frac-
tions were used for Western blot analysis. Samples were elec-
trophoresed on 10 % acrylamide gels and transferred onto
Fig. 1 Glucocorticoid-driven biochemical and structural correlates of
neuronal atrophy and memory deficits: a–c GC-treated animals
exhibited increased latency to escaping platform during the four
learning days of Morris water maze test compared to control (saline)
animals (a) as well as reduced numbers crossing from the platform area
(b) while no difference of percentage of time swam in target quadrant
between the two groups was found in probe test (c). d–g Morphometric
analysis of Golgi-impregnated hippocampal neurons showed that GC
treatment reduced the number of branches in apical but not basal
dendrites (d) followed by reduced spine density in both proximal and
distal parts of apical dendrites (e, g). Specifically, GC evoked a clear
reduction of density of mature/complex spines (f, g (i, iii, iv)) but not
immature/thin ones (e, f (ii)). h Schematic representation of the
subcellular fractionation protocol followed in this study for separating
P1 (nuclear pellet and debri), P2 (crude synaptosomal fraction), P3
(light membranes), S3 (cytosolic fractions), LP1 (synaptosomal
membrane fractions), LP2 (synaptic vesicle-enriched fraction), LS2
(soluble synaptosomal fraction)—for details, see Methods. i Western
blot analysis of cytosolic and synaptosomal fraction where PSD-related
scaffold proteins and receptors are found at synaptosomal, but not at
cytosolic, fraction. j, k Representative blots and quantitative WB
analysis of scaffold proteins showing that GC significantly decreased
PSD-95 and Shank levels in synaptosomal fraction compared to control
animals. l, m Levels of stable detyrosinated, but not acetylated, tubulin
were reduced in dorsal hippocampus of GC-treated animals. All graphical
data is shown as group mean±SEM; *p<0.05; **p<0.01; ***p<0.001
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nitrocellulose membranes (Trans-Blot® Turbo™ Blotting Sys-
tem, BioRad). Membranes were blocked in 5 % nonfat milk in
TBS-T buffer before incubation with the following antibodies:
PSD-95 (1:20000, NeuroMab), GluA2 (1:1000, Abcam),
GluN2B (1:1000, Abcam), pTyr1472-GluN2B (1:1000, Cell
Signaling) pan-Shank (1:20, NeuroMab), Fyn (1:200, Santa
Cruz), detyrosinated-Tubulin (1:1000, Abcam), acetylated-
Tubulin (1:500, Abcam), α-Tubulin (1:2000, DSHB), Tau-5
(1:2000, Abcam), p199/202-Tau (1:1000, Abcam), pThr231-
Tau (1:1000 Abcam), pSer262-Tau (1:250, Santa Cruz), p396-
Tau (1:5000, Abcam), PHF1 (1:1000; kindly provided by Dr. P.
Davies, Albert Einstein College, USA) cdk5 (1:2000,
Millipore), total GSK3 α/β (1:2000, Invitrogen), phospho-
Tyr279/216-GSK3α/β (1:2000, Invitrogen), and actin (1:2000,
DSHB). After incubation with the appropriate secondary anti-
body, antigens were revealed by ECL (Clarity, Bio-Rad). ECL
films (GE Healthcare) were used for detection of antigen signal
and films were scanned and quantified using TINA 3.0
bioimaging software (Raytest). All values were normalized
and expressed as percentages of controls. As previously shown
[16], the protocol fractionation efficiency of the hippocampal
tissue was confirmed using different synaptic proteins (see
above) that were exclusively found in synaptosomal but not in
cytosolic fraction (see Fig. 1g).
Statistical Analysis
All data were evaluated by GraphPad software (version 6, La
Jolla, CA, USA) using Student t test while Morris water maze
learning curve data were analyzed by repeated-measurements
ANOVA. Differences were considered to be significant if
p<0.05. Results are expressed as group means±SEM.
Results
Behavioral and Neurostructural Correlates of Prolong
Exposure to Glucocorticoids
For evaluating the impact of prolong GC treatment on
hippocampus-dependent spatialmemory,we used theMWMtest
and we found a significant increase in the time that GC-treated
(GC) animals needed to find the escaping platform, confirming a
deficit in spatial reference memory (p<0.05) (Fig. 1a). In addi-
tion, we found that animals exposed to GC exhibited lower num-
ber of crosses at the platform area supporting further the
memory-impairing role of GC (p=0.028) (Fig. 1b). However,
there is no difference between the two groups in the percentage
of time that animals swam into target quadrant during probe test
(Fig. 1c; p=0.14), indicating that at the end of the experiment all
animals were able to learn the task.
As neuroplastic changes and synaptic loss are robust cor-
relates of impaired cognitive behavior, we next analyzed the
entire dendritic tree of hippocampal CA1 pyramidal neurons
using unbiased 3D morphometric analysis of Golgi-
impregnated pyramidal neurons. We found that GC treatment
altered the dendritic arborization in pyramidal neurons by
diminishing the number of branches in apical, but not basal,
dendrites (p=0.03 and p=0.37, respectively; Fig. 1d). Further-
more, spine density was reduced in both proximal and distal
segments of apical dendrites (p=0.017 and p=0.007, respec-
tively; Fig. 1e, g). Moreover, when we clustered the spine
analysis in immature (thin) and mature (complex) categories
based on morphological characteristics [15] (see Fig. 1g (i–
iv)), we found that the density of mature/complex was reduced
by GC treatment (p=0.038) but no differences were found in
immature ones (Fig. 1f). Note that immature (thin) spines are
thought to be particularly plastic and linked to learning pro-
cess while mature spines (e.g., mushroom) are more stable
type of spines and believed to be involved in memory
formation.
Glucocorticoids Triggers Tau Hyperphosphorylation
and Missorting in Hippocampal Synapses
For monitoring the molecular underpinnings of the GC-
evoked dendritic remodeling and synaptic loss, we then per-
formed a detailed subcellular fractionation and organelle en-
richment protocol which allows us to distinguish between cy-
tosolic (excluding light membrane and Golgi fraction; S3) and
synaptosomal fractions (LP1; see Fig. 1h; for more details, see
“Methods” sections); as a confirmation of the efficacy of the
separation protocol, postsynaptic density proteins (e.g., post-
synaptic density protein 95; PSD-95) and synaptic receptors
(e.g., GluN2B) were not found in cytoplasmic fraction
(Fig. 1i). Next, we compared the synaptic and cytoskeletal
proteins whose alterations reflect plastic changes and found
that GC treatment reduced total levels of two proteins that play
a central role in the assembling of the synaptic molecular
components and transmission, PSD-95 and Shank scaffold
proteins in synaptosomal fraction (p=0.008 and p=0.015, re-
spectively; Fig. 1j, k); of notice, Fyn levels were not altered. In
addition, we found a significant reduction of stable,
detyrosinated tubulin levels (p<0.0001), while acetylated tu-
bulin was not different between GC-treated and controls
(Fig. 1l, m).
We next monitored the influence of GC on intracellular
distribution of Tau proteins and their phosphorylated iso-
forms. As shown at Fig. 2a, b, our subcellular fractionation-
based WB analysis revealed that chronic GC exposure in-
duced a significant increase in total cytosolic Tau levels (p=
0.003), as detected by the pan-Tau antibody Tau5 (that recog-
nizes both phosphorylated and nonphosphorylated protein
isoforms), which indicates a cytoplasmic accumulation of
Tau. In addition, we observed a significant increase in cyto-
solic fractions of normalized levels of phosphorylated
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isoforms, pThr231-Tau (p=0.023), pSer262-Tau (p=0.015),
and pSer396 (p=0.03) in the hippocampus of GC-treated rats,
but no effect of GC on pSer199/202 (Fig. 2a, b). Next, our
analysis focused on the synaptosomal fraction where we
found that overall Tau protein levels were also elevated by
GC treatment (p=0.01; Fig. 2c, d) pointing to synaptic accu-
mulation of Tau. Similar to the cytosolic fraction, levels of
normalized pSer199/202-Tau were not altered by GC
treatment, whereas pSer396-Tau was increased in the synap-
tosomal fraction (p<0.001). In contrast to the cytosolic com-
partment, pThr231-Tau synaptosomal levels were reduced af-
ter GC treatment (p<0.02), while no changes were detected on
pSer262-Tau levels. Next, we monitored the protein levels of
cyclin-dependent kinase 5 (cdk5) and glycogen synthase ki-
nase 3 (GSK-3), two key kinases that essentially contribute to
Tau hyperphosphorylation and malfunction and known to be
Fig. 2 GC-triggered Tau missorting at hippocampal synapses. a–d
Subcellular distribution of Tau and assessment of its phosphorylation
state at different biochemically separated fractions in control and GC-
treated hippocampi. GC evoked an accumulation of total Tau protein as
detected by increased Tau-5 levels in both cytosolic (a, b) and
synaptosomal fractions (c, d). In addition, normalized levels of
pThr231-Tau, pSer262-Tau, pSer396-Tau, and p396/404-Tau (PHF-1)
were increased in cytosolic fraction of GC-treated hippocampi but no
GC effect was detected on pSer199/202-Tau. In contrast, synaptosomal
levels of pThr231-Tau were decreased by GC while pSer262-Tau
remained unaltered. Similarly to cytosol, p-Ser396-Tau and PHF-1 Tau
levels were increased after GC treatment while levels of pSer199/202
were not altered. e–f GC increased protein levels of two key kinases of
Tau hyperphosphorylation, cdk5 and active-GSK3β (pTyr216-GSK3β)
accompanied by elevated levels of p-Tyr1472-Glu2B receptors. Numeric
data shown represent±SEM values as percentage of controls; *p<0.05;
**p<0.01; ***p<0.001
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involved in regulation of synaptic function. We found that GC
trigger increased protein levels of cdk5 (p=0.01) but did not
change the total levels of the two isoforms of GSK3 (α andβ).
However, levels of active-GSK3β (phospho-Tyr216-GSK3β)
were elevated by GC (p=0.001) while this GC effect was not
true for active-GSK3α (phospho-Tyr279-GSK3α) (Fig. 2e).
In the light of the recently suggested interaction of Tau with
synaptic proteins and receptors [7], we also monitored the
impact of GC on these proteins finding an clear increase in
the levels of phospho-Tyr1472 GluN2R, a phosphorylation
type suggestive to reflect activated GluN2R.
Ultrastructural Evidence of Tau Accumulation
and Missorting in Dendrites and Spines of GC-Treated
Hippocampus
As Tau intracellular localization and association to MTs and
membranes seems to be regulated by its phosphorylation state
[9, 11, 17, 18], we next monitor the localization and distribu-
tion of Tau, as well as its different phosphorylated forms,
using transmission electron microscopy (TEM). As it was
recently shown by us and others [8, 19], we found that Tau
protein was detected at the rat hippocampal dendrites (Fig. 3
(I, IV)), as well as in synapses (Fig. 3 (II, III)). Moreover, as
summarized in Table 1, we found that the density of total Tau
was increased in both dendrites and synapses of hippocampal
neurons of GC-treated animals (p<0.0001 for both); these
findings confirm our molecular data obtained byWB analysis.
In addition, chronic GC treatment resulted in increased densi-
ty of pSer262-Tau at dendrites (p<0.001), but no significant
alterations in synapses (p=0.10). Similarly, pSer396-Tau den-
sity in dendrites of hippocampus neurons was also significant-
ly increased by GC treatment (p=0.044), but there was only a
trend for an increase at the synaptic level. Note that p199/202-
Tau levels were not affected by GC in both dendrites and
synapses in line with our WB analysis findings. In addition,
we found a characteristic PHF1 immunogold staining in hip-
pocampal neurons of GC-treated animals (Fig. 2g (iv)), indi-
cating the presence of Tau aggregates [20]. In summary, elec-
tron microscope analysis of different Tau isoforms (both
phosphorylation-dependent and independent ones) suggest
that GC trigger Tau accumulation and missorting in dendrites
and spines of hippocampal neurons providing further support
to the above described biochemical findings.
Discussion
Through its interaction with several cellular partners such as
tubulin, F-actin, and Src family kinases, Tau seems to play an
important role in mediating alterations in the cytoskeletal
structure [21]. Besides its predominant localization at axons,
several observations suggest the presence and accumulation of
Tau at somatodendritic compartment (e.g., dendritic spines)
using cellular or animals models of Tau overexpression [6,
7, 9]. The present study confirms the presence of endogenous
Tau in dendrites and synapses of the hippocampus of wild-
type, nontransgenic, rats, in line with previous cell culture and
in vivo studies [8, 19]. In an extension of our previous find-
ings [13, 14], we now show that GC trigger the accumulation
of different isoforms of Tau in both dendritic and synaptic
compartments, which is an indicator of neuronal malfunction
and pathology. Indeed, accumulation of hyperphosphorylated
Tau has been shown to result in destabilization of the dendritic
cytoskeleton and compromised intracellular trafficking
[22–24]. As we found no GC-evoked changes in mRNA
levels of Tau (data not shown), which is in line with previous
cellular and animals studies [14, 25], the source of this Tau
accumulation could be attributed to GC-induced reduction of
Tau turnover [14] probably involving diminished Tau degra-
dation [26]; alternatively, changes in Tau phosphorylation
state might disrupt MT-Tau interactions liberating Tau from
MTs into the dendritic shafts from where it may diffuse to
spines and even to the synaptic compartment [6].
The intracellular distribution of Tau is largely regulated by
its phosphorylation status [9, 11, 17, 18]. In agreement with
previous studies [13, 14], we found that GC triggers Tau
hyperphosphorylation at specific sites (Thr231, Ser262,
Ser396, and/or Ser396/404); for example, Tau phosphoryla-
tion at the pSer199/202 epitope is not affected by GC suggest-
ing that GC impact of Tau phosphorylation is not global.
Moreover, in contrast to pThr231-Tau which plays an impor-
tant role in early AD pathology, hyperphosphorylation of the
199/202 and 212/214 epitopes of Tau appear at later stages of
the disease [27]. Thus, our GC-driven findings may be rele-
vant to the earliest stages of cytoskeletal disturbances where
Tau is believed to contribute to synaptic dysfunction and at-
rophy. This notion is further supported by the fact that GC-
triggered dendritic remodeling was limited to reduced dendrit-
ic branching and spine loss. It is also pertinent to mention that
Tau hyperphosphorylation at epitopes Thr231 and Ser262,
both altered by GC, correlates strongly with reduced microtu-
bule binding capacity of Tau and therefore, cytoskeletal dis-
turbances [28, 29]. Consistently, we observed that GC-evoked
Tau hyperphosphorylation occurs in tandem with decreased
levels of the stable detyrosinated microtubules, suggestive of
reduced microtubule stability [30, 31] that may be causally
related to the dendritic remodeling that occurs after stress [3,
32].
Interestingly, GC impact on Tau phosphorylation state ex-
hibited a subcellular and distinct pattern. Normalized
pThr231-Tau levels were increased in cytosol, but decreased
in synaptosomal fraction while p262-Tau levels were in-
creased only in cytosol (not in synaptic fraction detected by
WB or at spines as monitored by TEM), suggesting a prefer-
ential subcellular localization and/or accumulation of different
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Tau isoforms in both intracellular compartments after GC
treatment. It is suggested that different pools of Tau with dif-
ferent phosphorylation state exist within the neuron exhibiting
potentially distinct roles. For example, blockage of Tau phos-
phorylation at Ser396/404 is necessary for Aβ-driven mislo-
cation of Tau at synapses [6], while Tau phosphorylation at
pThr231, but not at other epitopes, regulates its synaptic bind-
ing to PSD-95 [19]. Interestingly, we found that the levels of
PSD95, a crucial protein for synaptic structure and function,
were reduced by the exposure to GCs, consistent with our
finding of synaptic loss using Golgi-based neuronal structural
analysis. Moreover, the reduction of PSD95 levels was ac-
companied by GC-driven decrease in levels of pThr231-Tau
within synaptosomal fraction, further supporting the previous-
ly suggested interrelationship between this phospho-Tau iso-
form and PSD95 [6]. Note that, with one minor exception
(p396-Tau), similar results regarding the differential distribu-
tion of phospho-Tau isoforms in different parts of the cell were
obtained using two different technical approaches (electron
microscopy and WB analysis of different subcellular frac-
tions) (see Fig. 2d and Table 1). Nevertheless, the complemen-
tary approaches (subcellular fractionation-based biochemical
analysis and in-situ ultrastructural detection) allowed a de-
tailed “mapping” of the presence of Tau in different intracel-
lular compartments. Our future efforts will aim to clarify the
role of GC on the intraneuronal dynamics of Tau, with partic-
ular focus on individual phosphorylation epitopes as well as
on the mechanisms through which GC and/or stress interfere
with the Tau sorting and clearance machinery in cytosolic and
synaptic compartments.
Recent studies show that Tau mislocation at dendritic spine is
a common feature observed in AD [11] as well as other
Tauopathies (FTP, FTDP-17) [9]; in parallel, increasing attention
and support has been given to the essential involvement of Tau
missorting in spine toxicity and synaptic pathology [19, 33]. A
previous study demonstrated that local Tau missorting induced
by Aβ or glutamate was followed by local spine loss and cyto-
skeletal disruption [24]; importantly, this Tau mislocation at syn-
apses are shown to depend on Tau hyperphosphorylation
[19, 34]. Besides Tau hyperphosphorylation, GCs are known to
trigger APPmisprocessing andAβ generation [14, 25, 35] while
Aβ is shown to trigger Tau hyperphosphorylation by inducing
different kinases such as GSK3β and cdk5 [36]. While further
studies are needed to clarify the interplay between Aβ, gluta-
mate, and Tau in stress/GC-triggered neuronal remodeling and
spine the notion atrophy, the present study provides evidence that
supports that GC can also influence the intracellular trafficking
of specific phospho-Tau isoforms and their missorting in synap-
ses. Indeed, as previously suggested by studies in animal models
of AD, abnormal Tau hyperphosphorylation and synaptic
Fig. 3 Ultrastructural detection
of different Tau isoforms in
hippocampal dendrites and
spines. Electron microscope
image of Tau-immunogold in
dorsal hippocampus showing that
Tau protein is detected in
dendrites (I) and synapses (II, III)
followed by negative controls (V).
In addition, note a characteristic
form of PHF1-detected Tau
immunostaining resembling to
aggregates in GC-treated neurons
Table 1 Quantification of immunogold analysis of different phospho-Tau isoforms and total Tau
Dendritic density Synaptic density
CON GC CON GC
Total Tau (#/μm2) 10.36±0.52 14.20±0.50*** 5.33±0.68 10.48±0.73**
p199/202-Tau (#/μm2) 11.41±0.69 12,78±1.32 11.74±2.15 9.46±1.46
p262-Tau (#/μm2) 12.23±0.48 24.19±1.75*** 8.82±1.98 6.87±1.82
p396-Tau (#/μm2) 7.15±0.49 9.42±0.71* 4.46±0.69 5.99±1.20
Electron microscope-based density (per μm2 ) of total Tau and different phosphorylated forms of Tau in both dendrites and synapses of hippocampal
neurons. Numerical data represent mean±SEM; *p<0.05; **p<0.01; ***p<0.001
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missorting results in damage to synaptic structure and
function, including postsynaptic receptor targeting and
function of excitatory glutamate receptor in dendritic
spines and leading to dendritic spine loss.[7, 9, 37]. In
line with this, we here showed that prolonged exposure to
elevated GC levels upregulate active (phosphoTyr1472)
GluN2B receptor units and subsequently, reduced levels of
synaptic scaffold/anchor proteins, such as PSD-95 and Shank,
and loss of spines. These findings provide new insights into the
cellular cascades triggered by GC and, in particular, highlight
the potentially important role of Tau hyperphosphorylation in
neuronal and synaptic malfunction and atrophy underlying
prolong exposure to elevated GC levels and related hippocam-
pal pathology.
In summary, the results reported here represent the first
description of GC-induced Tau missorting as a mechanism(s)
underlying synaptic atrophy and damage, beyondAlzheimer’s
disease pathology adding to our knowledge about the poorly
understood cellular cascades responsible for stress-related
brain pathology.
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